MedroxyPROGESTERone acetate injectable suspension, USP

150 mg/mL for intramuscular use

Medroxyprogesterone acetate injectable suspension is a progestin indicated for use by females of reproductive potential to prevent pregnancy. Limitations of Use: The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate.

Compares To

Depo-Provera®

NDC#

50102-591-40

View Full Prescribing Information, Including Boxed Warning

Product Details

  • Ready to use, available in a prefilled syringe containing 150 mg of medroxyprogesterone acetate injectable suspension for use every 3 months (13 weeks)

Product Sheet

The Product Information Sheet features a summary of all relevant product information including MedroxyPROGESTERone acetate injectable suspension, USP product details, product description, NDC number, and product features.

Download Now

Product Features:

  • An estrogen-free contraceptive
  • Offers effective and discreet pregnancy prevention that does not require daily action
  • Requires re-injection every 3 months (13 weeks), or only 4 times a year, at a healthcare provider

Limitations of Use: The use of medroxyPROGESTERone acetate injectable suspension is not recommended as a long-term (ie, longer than 2 years) birth control method unless other options are considered inadequate.

Women who use medroxyPROGESTERone acetate injectable suspension may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible.

It is unknown if use of medroxyPROGESTERone acetate injectable suspension during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone mass and increase the risk for osteoporotic fracture in later life MedroxyPROGESTERone acetate injectable suspension is not recommended as a long-term (ie, longer than 2 years) birth control method unless other options are considered inadequate.

The most common adverse reactions seen in medroxyPROGESTERone acetate injectable suspension, USP (incidence >5%) include: menstrual irregularities (57% at 12 months, 32% at 24 months), abdominal pain/discomfort (11%), weight gain >10 lbs at 24 months (38%), dizziness (6%), headache (17%), nervousness (11%), decreased libido (6%).

MedroxyPROGESTERone acetate injectable suspension does not protect against HIV infection (AIDS) and other sexually transmitted diseases (STDs).

View Full Prescribing Information, Including Boxed Warning

Distributor & Ordering Info

MedroxyPROGESTERone acetate injectable suspension, USP

NDC#: 50102-591-40

Package Size: 1 Carton Containing 1 Prefilled Syringe

Distributor Phone URL Order Number
ANDA 1-800-331-2632 (Ext. 74591) andanet.com 805071
ASD Healthcare 1-800-746-6273 asdhealthcare.com 58479
Cardinal Health 1-800-326-6457 cardinalhealth.com 5678271
McKesson 1-855-625-6285 mckesson.com 3565454
Morris & Dickson 1-888-376-7409 morrisdickson.com 915298
R & S Northeast 1-800-262-7770 rsnortheast.com 0591400

Order MedroxyPROGESTERone acetate injectable suspension, USP

Order Now


Contact Your
Afaxys Pharma
Account Manager

Contact Now


View All
Afaxys Pharma
Products

View Now
Need help? Contact an Afaxys Account Manager